Bevacizumab and osteonecrosis of the jaw: Incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer

Breast Cancer Research and Treatment

Volumn 122, Issue 1, 2010, Pages 181-188

  Guarneri, Valentina ^a   Miles, David ^b   Robert, Nicholas ^c   Diéras, Véronique ^d   Glaspy, John ^e   Smith, Ian ^f   Thomssen, Christoph ^g   Biganzoli, Laura ^h   Taran, Tanya ⁱ   Conte, Pierfranco ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b MOUNT VERNON CANCER CENTRE   (United Kingdom)

^c Fairfax Northern Virginia Hematology Oncology   (United States)

^d INSTITUT CURIE   (France)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f ROYAL MARSDEN HOSPITAL   (United Kingdom)

^g MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^h ISTITUTO TOSCANO TUMORI   (Italy)

ⁱ F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

Angiogenesis; Bevacizumab; Bisphosphonate; Metastatic breast cancer; Osteonecrosis of the jaw

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; BEVACIZUMAB; BISPHOSPHONIC ACID DERIVATIVE; CAPECITABINE; CLODRONIC ACID; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; IBANDRONIC ACID; NAVELBINE; NYSTATIN; PACLITAXEL; PAMIDRONIC ACID; PLACEBO; ZOLEDRONIC ACID; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; TAXOID; VINBLASTINE;

ABSCESS; ARTICLE; BREAST CANCER; CLINICAL TRIAL; DECORTICATION; DRUG EFFICACY; DRUG EXPOSURE; DRUG SAFETY; DRUG WITHDRAWAL; HUMAN; JAW DISEASE; JAW OSTEONECROSIS; MOUTH EXAMINATION; MOUTH HYGIENE; ORAL SURGERY; OSTEOMYELITIS; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RISK ASSESSMENT; TOOTH EXTRACTION; WOUND DEHISCENCE; AGED; ANALOGS AND DERIVATIVES; BREAST NEOPLASMS; CHEMICALLY INDUCED; COMPLICATION; DOUBLE BLIND PROCEDURE; DRUG POTENTIATION; FEMALE; GENETICS; INCIDENCE; JAW DISEASES; METASTASIS; MIDDLE AGED; MULTICENTER STUDY (TOPIC); OSTEONECROSIS; PATHOLOGY; PROSPECTIVE STUDY; PROTO ONCOGENE; RANDOMIZED CONTROLLED TRIAL (TOPIC); STATISTICS AND NUMERICAL DATA;

AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DIPHOSPHONATES; DOUBLE-BLIND METHOD; DRUG SYNERGISM; FEMALE; GENES, ERBB-2; HUMANS; INCIDENCE; JAW DISEASES; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; NEOPLASM METASTASIS; ORAL HYGIENE; OSTEONECROSIS; PACLITAXEL; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TAXOIDS; VINBLASTINE; ANTIBODIES, MONOCLONAL, HUMANIZED;

EID: 77953534421     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-010-0866-3     Document Type: Article

References (40)

1. K Miller M Wang J Gralow M Dickler M Cobleigh EA Perez T Shenkier D Cella NE Davidson 2007 Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer N Engl J Med 357 2666 2676 10.1056/NEJMoa072113 1:CAS:528:DC%2BD1cXisVOnsg%3D%3D 18160686
2. Miles D, Chan A, Romieu G Dirix LY, Cortes J, Pivot X, Tomczak P, Taran T, Harbeck N, Steger GG (2008) Randomized, double-blind, placebo-controlled, phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metastatic breast cancer (mBC): AVADO. J Clin Oncol 26(Suppl): (Abstract LBA1011)
3. Robert NJ, Dieras V, Glaspy J et al. (2009) RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab (B) for first-line treatment of HER2-negative locally recurrent or metastatic breast cancer (MBC). J Clin Oncol 27(15s): (Abstract 1005)
4. SA Cannistra UA Matulonis RT Penson J Hambleton J Dupont H Mackey J Douglas RA Burger D Armstrong R Wenham W McGuire 2007 Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer J Clin Oncol 25 5180 5186 10.1200/JCO.2007.12.0782 1:CAS:528:DC%2BD2sXhsVKnsbzM 18024865 (Pubitemid 350232248)
5. S Hapani D Chu S Wu 2009 Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis Lancet Oncol 10 559 568 10.1016/S1470-2045(09)70112-3 1:CAS:528:DC%2BD1MXms12jtbk%3D 19482548
6. IR Reid T Cundy 2009 Osteonecrosis of the jaw Skelet Radiol 38 5 9 10.1007/s00256-008-0549-x
7. AO Hoff BB Toth K Altundag MM Johnson CL Warneke M Hu A Nooka G Sayegh V Guarneri K Desrouleaux J Cui A Adamus RF Gagel GN Hortobagyi 2008 Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates J Bone Miner Res 23 826 836 10.1359/jbmr.080205 1:CAS:528:DC%2BD1cXnvVGjs70%3D 18558816 (Pubitemid 351768801)
8. A Bamias E Kastritis C Bamia LA Moulopoulos I Melakopoulos G Bozas V Koutsoukou D Gika A Anagnostopoulos C Papadimitriou E Terpos MA Dimopoulos 2005 Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors J Clin Oncol 23 8580 8587 10.1200/JCO.2005.02.8670 16314620 (Pubitemid 46211499)
9. JB Aragon-Ching YM Ning CC Chen L Latham JP Guadagnini JL Gulley PM Arlen JJ Wright H Parnes WD Figg WL Dahut 2009 Higher incidence of osteonecrosis of the jaw (ONJ) in patients with metastatic castration resistant prostate cancer treated with anti-angiogenic agents Cancer Invest 27 221 226 10.1080/07357900802208608 1:CAS:528:DC%2BD1MXktFKitbg%3D 19235596
10. G Sanna L Preda R Bruschini M Cossu Rocca S Ferretti L Adamoli E Verri L Franceschelli A Goldhirsch F Nolè 2006 Bisphosphonates and jaw osteonecrosis in patients with advanced breast cancer Ann Oncol 17 1512 1516 10.1093/annonc/mdl163 1:STN:280:DC%2BD28rnsFyktw%3D%3D 16936182 (Pubitemid 44542036)
11. BG Durie M Katz J Crowley 2005 Osteonecrosis of the jaw and bisphosphonates N Engl J Med 353 99 102 10.1056/NEJM200507073530120 1:CAS:528:DC%2BD2MXmtVWgsLY%3D 16000365 (Pubitemid 41007817)
12. C Walter B Al-Nawas A du Bois L Buch P Harter KA Grötz 2009 Incidence of bisphosphonate-associated osteonecrosis of the jaws in breast cancer patients Cancer 115 1631 1637 10.1002/cncr.24119 1:CAS:528: DC%2BD1MXltVOntLg%3D 19156913
13. V Guarneri S Donati M Nicolini S Giovannelli R D'Amico PF Conte 2005 Renal safety and efficacy of i.v. bisphosphonates in patients with skeletal metastases treated for up to 10 years Oncologist 10 842 848 10.1634/ theoncologist.10-10-842 1:CAS:528:DC%2BD28XltVakug%3D%3D 16314295 (Pubitemid 43152702)
14. EP Wang LB Kaban GJ Strewler N Raje MJ Troulis 2007 Incidence of osteonecrosis of the jaw in patients with multiple myeloma and breast or prostate cancer on intravenous bisphosphonate therapy J Oral Maxillofac Surg 65 1328 1331 10.1016/j.joms.2007.03.006 17577497 (Pubitemid 46915477)
15. T Fehm V Beck M Banys HP Lipp M Hairass S Reinert EF Solomayer D Wallwiener M Krimmel 2009 Bisphosphonate-induced osteonecrosis of the jaw (ONJ): incidence and risk factors in patients with breast cancer and gynaecological malignancies Gynecol Oncol 112 605 609 10.1016/j.ygyno.2008.11.029 1:CAS:528:DC%2BD1MXisVOhsr0%3D 19136147
16. MR Allen DB Burr 2009 The pathogenesis of bisphosphonate-related osteonecrosis of the jaw: so many hypotheses, so few data J Oral Maxillofac Surg 67 5 Suppl 61 70 10.1016/j.joms.2009.01.007 19371816
17. B Vincenzi D Santini L Rocci G Tonini 2003 Bisphosphonates: new antiangiogenic molecules in cancer treatment? Ann Oncol 14 806 10.1093/annonc/mdg194 1:STN:280:DC%2BD3s7otlehtw%3D%3D 12702541 (Pubitemid 36621787)
18. D Santini B Vincenzi S Galluzzo F Battistoni L Rocci O Venditti G Schiavon S Angeletti F Uzzalli M Caraglia G Dicuonzo G Tonini 2007 Repeated intermittent low-dose therapy with zoledronic acid induces an early, sustained, and long-lasting decrease of peripheral vascular endothelial growth factor levels in cancer patients Clin Cancer Res 13 15 Pt 1 4482 4486 10.1158/1078-0432.CCR-07-0551 1:CAS:528:DC%2BD2sXotlGqtb4%3D 17671133 (Pubitemid 47219717)
19. CL Estilo M Fornier A Farooki D Carlson G Bohle 3rd JM Huryn 2008 Osteonecrosis of the jaw related to bevacizumab J Clin Oncol 26 4037 4038 10.1200/JCO.2007.15.5424 18711196
20. S Greuter F Schmid T Ruhstaller B Thuerlimann 2008 Bevacizumab-associated osteonecrosis of the jaw Ann Oncol 19 2091 2092 10.1093/annonc/mdn653 1:STN:280:DC%2BD1cjlvVWmtQ%3D%3D 18977851
21. C Christodoulou A Pervena G Klouvas E Galani ME Falagas G Tsakalos A Visvikis A Nikolakopoulou V Acholos G Karapanagiotidis E Batziou DV Skarlos 2009 Combination of bisphosphonates and antiangiogenic factors induces osteonecrosis of the jaw more frequently than bisphosphonates alone Oncology 76 209 211 10.1159/000201931 1:CAS:528:DC%2BD1MXis12gsb4%3D 19212145
22. A Brunello G Saia A Bedogni D Scaglione U Basso 2009 Worsening of osteonecrosis of the jaw during treatment with sunitinib in a patient with metastatic renal cell carcinoma Bone 44 173 175 10.1016/j.bone.2008.08.132 1:CAS:528:DC%2BD1cXhsFahtLnP 18849018
23. Bonomi L, Bettini A, Bonacina R, Villa F, Mariani U, Rota Caremoli E, Tondini C (2009) Efficacy of a surveillance dental programme on prevention of osteonecrosis of the jaw in cancer patients with bone metastases: a single institution preliminary experience. Eur J Cancer Suppl 7:199 (Abstract 3082)
24. ML Cher DA Towler S Rafii D Rowley HJ Donahue E Keller M Herlyn EA Cho LW Chung 2006 Cancer interaction with the bone microenvironment Am J Pathol 168 1405 1412 10.2353/ajpath.2006.050874 1:CAS:528:DC%2BD28XkvF2nsLk%3D 16651608
25. M Nakagawa T Kaneda T Arakawa S Morita T Sato T Yomada K Hanada M Kumegawa Y Hakeda 2000 Vascular endothelial growth factor (VEGF) directly enhances osteoclastic bone resorption and survival of mature osteoclasts FEBS Lett 473 161 164 10.1016/S0014-5793(00)01520-9 1:CAS:528:DC%2BD3cXjt1ejtLY%3D 10812066 (Pubitemid 30254282)
26. SE Aldridge TW Lennard JR Williams MA Birch 2005 Vascular endothelial growth factor receptors in osteoclast differentiation and function Biochem Biophys Res Commun 335 793 798 10.1016/j.bbrc.2005.07.145 1:CAS:528: DC%2BD2MXpsVCgurc%3D 16105658 (Pubitemid 41188268)
27. RE Marx Y Sawatari M Fortin V Broumand 2005 Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment J Oral Maxillofac Surg 63 1567 1575 10.1016/j.joms.2005.07.010 16243172 (Pubitemid 41525412)
28. Cortes-Funes H, Pritchard KI, Biganzoli L, Thomssen C, Pierga J, Koza I, Kwong A, Kellokunpu-Lehitinen P, Chlistalla A, Smith I (2009) Multinational study (n = 2041) of first-line bevacizumab (Bev) plus taxane-based chemotherapy (CT) for locally recurrent or metastatic breast cancer (LR/mBC): updated results of MO19391. Eur J Cancer Suppl 7(2):265 (Abstract 5017)
29. HL McArthur C Estilo J Huryn T Williams M Fornier TA Traina J Howard CA Hudis MN Dickler 2008 Osteonecrosis of the jaw (ONJ) among intravenous (IV) bisphosphonate- and/or bevacizumab-treated patients (pts) at Memorial Sloan-Kettering Cancer Center (MSKCC) J Clin Oncol 26 9588
30. SB Woo JW Hellstein JR Kalmar 2006 Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws Ann Intern Med 144 753 761 1:CAS:528:DC%2BD28XlsFKhs70%3D 16702591
31. A Kyrgidis K Vahtsevanos G Koloutsos C Andreadis I Boukovinas Z Teleioudis A Patrikidou S Triaridis 2008 Bisphosphonate-related osteonecrosis of the jaws: a case-control study of risk factors in breast cancer patients J Clin Oncol 26 4634 4638 10.1200/JCO.2008.16.2768 18574158
32. D Mauri A Valachis IP Polyzos NP Polyzos K Kamposioras LL Pesce 2009 Osteonecrosis of the jaw and use of bisphosphonates in adjuvant breast cancer treatment: a meta-analysis Breast Cancer Res Treat 116 433 439 10.1007/s10549-009-0432-z 1:CAS:528:DC%2BD1MXhtFGmtrzI 19521766
33. AE King EM Umland 2008 Osteonecrosis of the jaw in patients receiving intravenous or oral bisphosphonates Pharmacotherapy 28 667 677 10.1592/phco.28.5.667 1:CAS:528:DC%2BD1cXmsVyrsr8%3D 18447663 (Pubitemid 351620033)
34. C Ortega F Montemurro R Faggiuolo R Vormola D Nanni F Goia MO Gilardino M Aglietta 2007 Osteonecrosis of the jaw in prostate cancer patients with bone metastases treated with zoledronate: a retrospective analysis Acta Oncol 46 664 668 10.1080/02841860601185917 1:CAS:528:DC%2BD2sXmsVOisL0%3D 17562443 (Pubitemid 46911907)
35. K Vahtsevanos A Kyrgidis E Verrou E Katodritou S Triaridis CG Andreadis I Boukovinas GE Koloutsos Z Teleioudis K Kitikidou P Paraskevopoulos K Zervas K Antoniades 2009 Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw J Clin Oncol 27 5356 5362 10.1200/JCO.2009.21.9584 1:CAS:528:DC%2BD1MXhsFKkt7rF 19805682
36. AA Khan GK Sándor E Dore AD Morrison M Alsahli F Amin E Peters DA Hanley SR Chaudry DW Dempster FH Glorieux AJ Neville RM Talwar CM Clokie M Al Mardini T Paul S Khosla RG Josse S Sutherland DK Lam RP Carmichael N Blanas D Kendler S Petak LG St-Marie J Brown AW Evans L Rios JE Compston Canadian Association of Oral, Maxillofacial Surgeons 2008 Canadian consensus practice guidelines for bisphosphonate associated osteonecrosis of the jaw J Rheumatol 35 1391 1397 18528958
37. M Dickinson HM Prince S Kirsa A Zannettino SD Gibbs L Mileshkin J O'Grady JF Seymour J Szer N Horvath DE Joshua 2009 Osteonecrosis of the jaw complicating bisphosphonate treatment for bone disease in multiple myeloma: an overview with recommendations for prevention and treatment Intern Med J 39 304 316 10.1111/j.1445-5994.2008.01824.x 1:CAS:528:DC%2BD1MXpt1Ontr4%3D 19220531
38. CJ Sweeney KD Miller SE Sissons S Nozaki DK Heilman J Shen GW Sledge Jr 2001 The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors Cancer Res 61 3369 3372 1:CAS:528:DC%2BD3MXjtFSjur4%3D 11309294
39. CI Ripamonti M Maniezzo T Campa E Fagnoni C Brunelli G Saibene C Bareggi L Ascani E Cislaghi 2009 Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan Ann Oncol 20 137 145 10.1093/annonc/mdn526 1:STN:280:DC%2BD1M%2Fns1ygug%3D%3D 18647964
40. BJ Edwards M Gounder J McKoy D Raisch M Farrugia M Cesar R Marx S Ruggiero M Dimopoulos C Bennett 2007 Bisphosphonate use and osteonecrosis of the jaw: pharmacovigilance and reporting of this serious adverse event from the Research on Adverse Drug Events and Reports (RADAR) project J Clin Oncol 25 18S 6519